CTSO - シトソ―ベンツ （Cytosorbents Corporation） シトソ―ベンツCTSOのチャート
CTSOの企業情報
| symbol | CTSO |
|---|---|
| 会社名 | Cytosorbents Corp （シトソ―ベンツ） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Medical/Dental Instruments |
| 業種 | 先端医療機器_テクノロジ― 医療関連（Health Care） |
| 概要 | 事業概要 CytoSorbents Corporation is a critical care focused immunotherapy company. The Company is engaged in commercializing its product CytoSorb which is a blood purification technology with focus in preventing or treating multiple organ failure. The Company's purification technologies are based on biocompatible porous polymer beads that remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. The Company's CytoSorb is an extracorporeal cytokine filter and is designed to reduce the cytokine storm that causes inflammation organ failure and death in common critical illnesses such as sepsis burn injury trauma lung injury and pancreatitis. In addition CytoSorb is used in other inflammatory conditions such as cardiac surgery and autoimmune disease flares and cancer cachexia. It also has other products under development based upon its blood purification technology including HemoDefend ContrastSorb DrugSorb BetaSorb and others. シトソ―ベンツは、免疫療法に特化した米国の医療会社。多臓器不全を治療するために炎症を調節する血液浄化技術プラットフォ―ムを使用して免疫療法を行う。欧州連合で、体外サイトカインフィルタ｢CytoSorb｣デバイスを販売する｡また血液浄化システム｢HomoDefend｣と血液から有毒な薬を取り除く｢DrugSorb｣を開発する。 |
| 本社所在地 | 7 Deer Park Drive Suite K Monmouth Junction NJ 08852 USA |
| 代表者氏名 | ― |
| 代表者役職名 | ― |
| 電話番号 | ― |
| 設立年月日 | 37347 |
| 市場名 | NASDAQ Small Cap |
| ipoyear | ―年 |
| 従業員数 | 84人 |
| url | www.cytosorbents.com |
| nasdaq_url | https://www.nasdaq.com/symbol/ctso |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -13.01103 |
| 終値（lastsale） | 11.61 |
| 時価総額（marketcap） | 365244133.23 |
| 時価総額 | 時価総額（百万ドル） 360.83980 |
| 売上高 | 売上高（百万ドル） 19.15110 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 345.45086 |
| 当期純利益 | 当期純利益（百万ドル） -14.00454 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Cytosorbents Corp revenues increased 60% to $10.7M. Net loss increased from $3.3M to $8.8M. Revenues reflect CytoSorb sales increase of 71% to $9.6M Other sales increase from $14K to $88K. Higher net loss reflects General and administrative -other increase of 49% to $7.8M (expense) Stock-based Compensation in SGA increase from $876K to $2.5M (expense). |
CTSOのテクニカル分析
CTSOのニュース
CytoSorbents To Start US Study With CytoSorb For Ticagrelor Removal 2021/04/19 16:22:57 Benzinga
The FDA has signed off conditional approval for the STAR-T study to assess CytoSorbents Corporation's (NASDAQ: CTSO ) blood purification device, CytoSorb, to remove Ticagrelor. The company can now initiate clinical trial agreement negotiations and institutional review board submissions. The randomized, controlled clinical trial was designed to support U.S. marketing submission for CytoSorb, to remove AstraZeneca Plc's (NASDAQ:
B. Braun Melsungen AG | B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® 2021/03/02 14:20:00 RealWire
Joint marketing of CytoSorb® with B. Braun’s newest OMNI® blood purification platform will offer greater access of this advanced treatment of deadly inflammation to critically ill patien…
B. Braun Avitum AG and CytoSorbents Corporation Announce Global Co-Marketing Agreement to Promote the OMNI® Continuous Blood Purification Platform with CytoSorb® 2021/03/02 12:00:00 Benzinga
MELSUNGEN, Germany and MONMOUTH JUNCTION, N.J. , March 2, 2021 /PRNewswire/ -- B. Braun Avitum AG, a leading manufacturer of medical devices and pharmaceutical products and services and CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader commercializing its CytoSorb ® blood purification technology to treat deadly inflammation, announce the launch of a global co-marketing agreement to promote the use of CytoSorb ® with B. Braun's latest OMNI ® continuous blood purification platform and OMNIset ® Plus bloodline set (set version 3.0 or higher). The CytoSorb ® adsorber is used in critical care for the extracorporeal removal of cytokines and inflammatory mediators from the bloodstream and can be operated with the B. Braun OMNI ® acute dialysis machine. B. Braun will supply the market with the OMNI ® and OMNIset ® Plus while CytoSorbents and its network of direct sales, strategic partners, and distributors will continue to supply the market with CytoSorb ® . CytoSorb ® is CE Mark certified and distributed in 67 countries worldwide.
CytoSorbents to Report Fiscal 2020 Operating and Financial Results 2021/03/01 23:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., March 1, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, will report…
Global Blood Purification Equipment Market Future Prediction Report By 2027 Top Companies CytoSorbents Corporation, Fresenius Medical Care. (NxStage Medical, Inc.), Spectral Medical Inc., Baxter International Inc., Nikkiso Co, Inc., Haemonetics Corporatio 2021/03/01 15:55:42 OpenPR
The blood purification equipment market accounted to US$ 3,881.3 Mn in 2018 and is expected to grow at a CAGR of 4.0% during the forecast period 2019 – 2027, to account to US$ 5,502.8 Mn by 2027. The report highlights the
CytoSorbents Appoints James Komsa as Vice President - U.S. Sales and Marketing 2021/01/11 11:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., Jan. 11, 2021 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world,…
CytoSorbents Pays Off $15M Term Loans and Establishes New Undrawn $15M Loan Commitment with Bridge Bank 2020/12/10 12:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., Dec. 10, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically ill and cardiac surgery patients around the world,…
CytoSorbents to Present at the Piper Sandler 32nd Annual Healthcare Conference 2020/11/23 12:00:00 PR Newswire
MONMOUTH JUNCTION, N.J., Nov. 23, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, is…
CytoSorbents to Present at the Jefferies Virtual London Healthcare Conference 2020/11/12 07:00:00 Benzinga
MONMOUTH JUNCTION, N.J. , Nov. 12, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO ), a critical care immunotherapy leader commercializing its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, announced that the Company will present an overview of the company at the Jefferies Virtual London Healthcare Conference on Tuesday, November 17, 2020 and meet with investors in 1x1 meetings throughout the day. For European investors, please contact your Jefferies representative to assist with scheduling. CTSO ) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb. CytoSorb is approved in the European Union and distributed in 58 countries worldwide. (PRNewsfoto/CytoSorbents Corporation)" alt="CytoSorbents Corporation (NASDAQ: CTSO ) is a leader in blood purification to treat cytokine storm and deadly inflammation in life-threatening illnesses with its flagship product, CytoSorb.
CytoSorbents Reports Record Third Quarter 2020 Financial Results 2020/11/04 21:15:00 PR Newswire
MONMOUTH JUNCTION, N.J., Nov. 4, 2020 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a critical care immunotherapy leader using its CytoSorb® blood purification technology to treat deadly inflammation in critically-ill and cardiac surgery patients around the world, reports its…